Matthew K. Fust
Independent DirectorMr. Matthew K. Fust, also known as Matt, M. B.A, was Board Observer of Star Therapeutics, Inc. Mr. Fust is Independent Director of Star Therapeutics, Inc. from December 2023. He serves as Independent Director at Electra Therapeutics, Inc. since November 2023. He serves as Director of Arsenal Biosciences, Inc. He has been a Director of Ultragenyx Pharmaceutical Inc. since January 30, 2014. He served as Director at Crinetics Pharmaceuticals, Inc. since February 2018 until September 1, 2026. Mr. Fust is a Board Member and advisor to life sciences companies. He has extensive experience in the life sciences industry and has financial experience. Mr. Fust served as the Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Onyx Pharmaceuticals, Inc. since January 5, 2009 until October 2013. Mr. Fust continued as an Employee of Amgen until January 2014. Mr. Fust served as the Chief Financial Officer at Jazz Pharmaceuticals Public Limited Company from May 2003 to December 31, 2008, Executive Vice President from March 2008 to December 31, 2008, Principal Accounting Officer until December 31, 2008 and Senior Vice President since 2004. He joined Jazz Pharmaceuticals in 2003. He served as the Chief Financial Officer of Perlegen Sciences, Inc. from May 2002 to May 2003. He served as a Senior Vice President and Chief Financial Officer of ALZA Corporation from 1996 to January 2002. At ALZA, he was responsible for the accounting, financial planning, information technology, internal audit, tax and treasury functions and served as its Vice President, Finance and Controller from 1998 to 1999 and an Executive Director (Accounting and Financial Reporting) from 1996 to 1998. From 1991 to 1996, he was a Manager in the healthcare strategy practice at Anderson Consulting. He was a Management Consultant in Andersen Consultant’s healthcare strategy practice for few years. Prior to joining ALZA, he was a member of the healthcare strategy consulting practice at Andersen Consulting (now Accenture). He served as a Director of MacroGenics, Inc. since March 6, 2014 until May 14, 2020. He serves as Business Advisor of Juvena Therapeutics, Inc. He has been an Independent Director at Atara Biotherapeutics, Inc. since March 2014. He served as a Non-Employee Director of Dermira Inc. since April 2014 until February 19, 2020. He was an Independent Director of Sunesis Pharmaceuticals, Inc. since May 2005 until May 2017 and serves as a Director of Project Inform, a nonprofit corporation. He is also an advisor to Out Leadership/Quorum and Women In Bio. He serves as an Independent Director at Neumora Therapeutics, Inc since December 2020. He served as a Board Observer of Ultragenyx Pharmaceutical Inc. since November 2013. Mr. Fust holds an MBA from the Graduate School of Business at Stanford University and a Bachelor of Arts in accounting degree from the University of Minnesota.
Positions
- Company NameUltragenyx Pharmaceutical Inc.Stock CodeRAREPositionIndependent DirectorColleagues
- EDEmil D. KakkisFounder, President, CEO & Director
- DGDaniel G. WelchIndependent Non-Executive Chairman
- HHHoward HornExecutive VP of Corporate Strategy & CFO
- KHKarah Herdman ParschauerChief Legal Officer & Executive VP of Corporate Affairs
- EHErik HarrisExecutive VP & Chief Commercial Officer
- ECEric CrombezChief Medical Officer & Executive VP
- MAMichael A. NarachiIndependent Director
- SSShehnaaz SulimanIndependent Director
- Company NameAtara Biotherapeutics, Inc.Stock CodeATRAPositionIndependent DirectorColleagues
- ANAnhco NguyenPresident, CEO & Director
- GAGregory Austin CiongoliIndependent Chairman
- KGKevin G. SarneyInterim Chief Financial Officer
- JSJim SesicSenior Vice President of Regulatory Affairs
- MKMatthew K. FustIndependent Director
- WKWilliam K. HeidenIndependent Director
- NSNachi SubramanianIndependent Director
- Company NameNeumora Therapeutics, Inc.Stock CodeNMRAPositionIndependent DirectorColleagues
- PLPaul L. BernsExecutive Chairman
- JPJoshua PintoPresident, CEO & Director
- DSDaljit Singh AuroraChief Operationg & Development officer
- MLMichael Lee MilliganCFO & Principal Accounting Officer
- NBNicholas BrandonChief Scientific Officer
- MKMatthew K. FustIndependent Director
- KMKristina M. BurowIndependent Director
- AHAlaa HalawaIndependent Director
- Company NameElectra Therapeutics, Inc.Stock CodeETRAPositionIndependent DirectorColleagues
- QDQuehuong DongPresident, CEO & Director
- NENancy E. StaglianoIndependent Chair
- GSGary S. KoeChief Technology Officer
- KDKim-Hien DaoChief Medical Officer
- CWChristopher William ClarkChief Financial Officer
- GPGraham ParryChief Scientific Officer
- CLCarl Lee GordonIndependent Director
- MKMatthew K. FustIndependent Director
